Jan30

Solid Biosciences Inc. (NASDAQ:SLDB), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per share.

Jan25

Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000.

A progressive genetic muscle wasting disease

Navigation title: 
What is DMD?
Background video: 
Images: 
Show particles: 
Show print button: 
Nov30

Today we are excited to announce the initiation of our first clinical trial for SGT-001.

Nov30

Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.

Simple Print Button

Background video: 
Show particles: 
Show print button: 

Simple Social Sharing Banner

Background video: 
Show particles: 

Glossary of Terms

There are a lot of complex scientific words used to describe gene therapy and Duchenne. We've compiled a glossary of some of the more commonly used terms.

View Glossary

Image: 
Navigation title: 
Glossary
Background video: 
Show particles: 
Show print button: 

Pages

More information about Solid?

Please subscribe to receive our latest news